Immunic to present four vidofludimus calcium abstracts at MSToronto2026 conference
Immunic Inc. announced that four abstracts on its investigational MS drug vidofludimus calcium have been accepted for presentation at the 10th Joint ACTRIMS‑ECTRIMS Meeting in Toronto from October 21‑23, 2026. The abstracts cover long‑term disability outcomes from the phase 2 CALLIPER trial open‑label extension, preclinical neuronal survival data, reductions in EBV‑specific T‑cell signatures linked to cognitive improvement, and a proposed bidirectional disability endpoint. Company CEO Erik Lundgren highlighted the data as evidence of the drug’s differentiated profile across the MS spectrum.
Why it matters
The company notes that the open‑label extension showed trends toward a lower risk of 24‑week confirmed disability worsening and low discontinuation rates, which could strengthen the clinical case for vidofludimus calcium as it advances toward regulatory review. No analyst or company earnings guidance was provided, so the immediate impact on investors is limited to potential future valuation changes as the data are evaluated.
Key facts
- 1Four abstracts on vidofludimus calcium were accepted for presentation at MSToronto2026. prnewswire.com
- 2The conference will be held October 21‑23, 2026 in Toronto, Canada. prnewswire.com
- 3The open‑label extension of the phase 2 CALLIPER trial reported data through week 48. prnewswire.com
- 4Trends toward a lower risk of 24‑week confirmed disability worsening were observed for participants receiving continuous vidofludimus calcium versus those switching from placebo. investing.com
- 5A high proportion of patients transitioned to the extension phase and discontinuation rates remained low. finance.yahoo.com
- 6Preclinical studies showed vidofludimus calcium promotes neuronal survival in human neuronal cells via Nurr1 and reduces disease severity and plasma neurofilament light chain in EAE models. finance.yahoo.com
Open questions
- The reported trends toward lower disability worsening are not quantified with statistical significance levels.
- No specific numerical results or p‑values were provided for the confirmed disability change endpoint.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.